[Form 4] PDS Biotechnology Corp Insider Trading Activity

Rhea-AI Filing Summary

Boesgaard Lars reported acquisition or exercise transactions in this Form 4 filing.

PDS Biotechnology Corp reported that Chief Financial Officer Lars Boesgaard received a grant of employee stock options covering 300,000 shares on January 12, 2026. These options give him the right to buy company stock in the future.

The options vest over four years. Twenty‑five percent of the underlying shares will vest and become exercisable on January 12, 2027, and the remaining 75% will vest in 36 equal monthly installments after that date, as long as he continues to serve the company through each vesting date.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Boesgaard Lars

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (Right to Buy)	300,000	$0.00	--

Holdings After Transaction: Employee Stock Option (Right to Buy) — 300,000 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Boesgaard Lars

(Last) (First) (Middle)

C/O PDS BIOTECHNOLOGY CORPORATION

303A COLLEGE ROAD EAST

(Street)

PRINCETON NJ 08540

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PDS Biotechnology Corp [ PDSB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$0.98	01/12/2026		A		300,000		(1)	01/12/2036	Common Stock	300,000	$0	300,000	D

Explanation of Responses:

1. The option will vest over four years, as follows: 25% of the shares underlying the option will vest and become exercisable on January 12, 2027, with the remaining 75% vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through each vesting date.

	/s/ Lars Boesgaard	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did PDSB CFO Lars Boesgaard report on this Form 4?

The filing shows CFO Lars Boesgaard received a grant of employee stock options for 300,000 shares. These options are a right to buy PDS Biotechnology Corp stock in the future, subject to a multi‑year vesting schedule and continued service conditions.

How many PDS Biotechnology (PDSB) stock options were granted to the CFO?

The CFO was granted employee stock options covering 300,000 shares of PDS Biotechnology Corp common stock. All 300,000 derivative securities were reported as directly owned following the grant, reflecting his full option award subject to vesting over the four‑year schedule.

What is the vesting schedule for the 300,000 PDSB stock options?

The options vest over four years. Twenty‑five percent of the shares vest and become exercisable on January 12, 2027, while the remaining 75% vest in 36 equal monthly installments thereafter, assuming the CFO continues serving the company through each vesting date.

Was there any purchase price disclosed for the PDSB stock option grant?

The reported transaction price per share for the employee stock options was 0.0000. This indicates the grant itself did not require a cash payment, consistent with typical equity compensation awards, though any future exercise terms would be governed by company plans and agreements.

Is the PDSB CFO’s option grant on this Form 4 a buy or sell transaction?

The transaction is classified as an acquisition of derivative securities through a grant or award, not an open‑market buy or sell. It reflects equity compensation to the CFO, with options that may be exercised in the future as they vest over the four‑year period.

What ownership type is shown for the PDSB CFO’s stock options after the grant?

The filing indicates direct ownership of 300,000 employee stock options by the CFO following the transaction. There is no reference to indirect ownership through another entity, and no footnote stating another party holds voting or investment power over these derivative securities.